ARTICLE | Targets & Mechanisms
A venture view of biological white space
VCs on BioCentury’s SAB weigh in on biological whitespace
April 11, 2019 11:14 PM UTC
Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data will be a wellspring of selectively targeted medicines across many indications.
In a roundtable discussion with BioCentury, 5 AM Ventures Managing Partner Kush Parmar, Flagship Pioneering Venture Partner Paul-Peter Tak and Third Rock Ventures Partner Reid Huber identified targets and tools that could form the basis for new classes of therapies. ...